ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
U.S. Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute): Opportunity Analysis and Industry Forecast, 2020–2027
Published Date: 2021-01-29
|
Report Code: ALLI-Auto-4W409
Home | Market Reports
U S Pain Management Drugs Market by Drug Class NSAIDS Anesthetics Anticonvulsant Anti Migraine Drugs Antidepressant Drugs Opioids Non Narcotics and Analgesics Indication Arthritic Pain Neuropathic Pain Cancer Pain Chronic Pain Post Operative Pain Migraine Fibromyalgia Bone Fracture Muscle Sprain Strain Acute Appendicitis and Other Indications Pain Type Chronic and Acute Opportunity Analysis and Industry Forecast 2020 2027

U.S. Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute): Opportunity Analysis and Industry Forecast, 2020–2027

Code: ALLI-Auto-4W409
Report
2021-01-29
Pages:153
Allied Market Research
Description
Table of Content
Tables & Figures

U.S. Pain Management Drugs Market Outlook: 2027

The U.S. pain management drugs market was valued at $31,499.07 million in 2019, and is projected to reach $39,356.45 million by 2027, registering a CAGR of 3.4%. Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer.

The length of the pain would range from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain when chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available, which provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.

Rise in geriatric population is the major factor that drives growth of the U.S. pain management drugs market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel the growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth. The U.S. pain management drugs market is segmented on the basis of drug class, indication, pain type, and region.

On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDS), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis and others. On the basis of pain type, the market is segmented into chronic and acute pain.

The key players operating in the U.S. pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Purdue Pharma L.P., Boehringer Ingelheim, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc.

Key Benefits for Stakeholders

  • This report entails a detailed quantitative analysis along with the current U.S. pain management drugs market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
  • The market forecast is studied from 2020 to 2027.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Drug Class

  • NSAIDS
  • Anesthetics
  • Anticonvulsants
  • Antimigraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Bone fracture
  • Muscle sprain/strain
  • Acute appendicitis
  • Others

By Pain type

  • Chronic pain
  • Acute pain
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in incidences of chronic diseases
3.5.1.2.Favorable regulatory scenario
3.5.1.3.Increase in geriatric population
3.5.2.Restraints
3.5.2.1.Availability of alternative therapies
3.5.2.2.Drug exploitation
3.5.2.3.Patent expiration of prescription drugs
3.5.3.Opportunity
3.5.3.1.Advancements in drug development
3.5.4.Impact Analysis
3.6.COVID-19 impact analysis for U.S. Pain Management Drugs
CHAPTER 4:U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.NSAIDS
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.3.Anesthetics
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.4.Anticonvulsants
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.5.Antimigraine drug
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.6.Antidepressants
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast
4.7.Opioids
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast
4.8.Non-narcotic analgesics
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast
CHAPTER 5:U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Arthritic pain
5.2.1.Market size and forecast
5.3.Neuropathic pain
5.3.1.Market size and forecast
5.4.Cancer pain
5.4.1.Market size and forecast
5.5.Chronic back pain
5.5.1.Market size and forecast
5.6.Post-operative pain
5.6.1.Market size and forecast
5.7.Migraine
5.7.1.Market size and forecast
5.8.Fibromyalgia
5.8.1.Market size and forecast
5.9.Bone fracture
5.9.1.Market size and forecast
5.10.Muscle sprain/strain
5.10.1.Market size and forecast
5.11.Acute appendicitis
5.11.1.Market size and forecast
5.12.Others
5.12.1.Market size and forecast
CHAPTER 6:PAIN MANAGEMENT DRUGS, BY PAIN TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Chronic pain
6.2.1.Market size and forecast
6.3.Acute pain
6.3.1.Market size and forecast
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.BOEHRINGER INGELHEIM INTERNATIONAL GMBH
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.3.ELI LILY AND COMPANY
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.GLAXOSMITHKLINE PLC (GSK)
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance.
7.4.6.Key strategic moves and developments
7.5.JOHNSON & JOHNSON
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.MERCK & CO., INC.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.MYLAN N.V.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments
7.8.NOVARTIS INTERNATIONAL AG
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.PFIZER INC.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.PURDUE PHARMA L.P.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and development
LIST OF TABLES

TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 03.PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 04.ABBOTT: COMPANY SNAPSHOT
TABLE 05.ABBOTT: OERATING SEGMENT
TABLE 06.ABBOTT: PRODUCT PORTFOLIO
TABLE 07.BOEHRINGER INGELHEIM : COMPANY SNAPSHOT
TABLE 08.BOEHRINGER INGELHEIM : OPERATING SEGMENTS
TABLE 09.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 10.ELI LILLY: COMPANY SNAPSHOT
TABLE 11.LILLY: OPERATING SEGMENTS
TABLE 12.ELI LILLY: PRODUCT PORTFOLIO
TABLE 13.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 14.GSK: COMPANY SNAPSHOT
TABLE 15.GSK: OPERATING SEGMENTS
TABLE 16.GSK: PRODUCT PORTFOLIO
TABLE 17.J&J: COMPANY SNAPSHOT
TABLE 18.J&J: OPERATING BUSINESS SEGMENTS
TABLE 19.J&J: PRODUCT PORTFOLIO
TABLE 20.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 21.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 22.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 23.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24.MYLAN: COMPANY SNAPSHOT
TABLE 25.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 26.MYLAN: PRODUCT PORTFOLIO
TABLE 27.NOVARTIS: COMPANY SNAPSHOT
TABLE 28.NOVARTIS: OPERATING SEGMENTS
TABLE 29.NOVARTIS: PRODUCT PORTFOLIO
TABLE 30.PFIZER: COMPANY SNAPSHOT
TABLE 31.PFIZER: OERATING SEGMENT
TABLE 32.PFIZER: PRODUCT PORTFOLIO
TABLE 33.PURDUE: COMPANY SNAPSHOT
TABLE 34.PURDUE: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01.PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 05.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 06.TOP PLAYER POSTIONING, 2019
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF SUBSTITUTES
FIGURE 10.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 11.MODERATE COMPETITIVE OF RIVALRY
FIGURE 12.IMPACT ANALYSIS, U.S. PAIN MANAGEMENT DRUGS MARKET
FIGURE 13.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS, 2019-2027 ($MILLION)
FIGURE 14.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANAESTHETIC, 2019-2027 ($MILLION)
FIGURE 15.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANTS, 2019-2027 ($MILLION)
FIGURE 16.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTI-MIGRAINE AGENTS, 2019-2027 ($MILLION)
FIGURE 17.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANTS, 2019-2027 ($MILLION)
FIGURE 18.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS, 2019-2027 ($MILLION)
FIGURE 19.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS, 2019-2027 ($MILLION)
FIGURE 20.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ARTHRITIC PAIN BY, 2019-2027 ($MILLION)
FIGURE 21.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN, 2019-2027 ($MILLION)
FIGURE 22.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN, 2019-2027 ($MILLION)
FIGURE 23.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK PAIN, 2019-2027 ($MILLION)
FIGURE 24.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN, 2019-2027 ($MILLION)
FIGURE 25.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE, 2019-2027 ($MILLION)
FIGURE 26.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA, 2019-2027 ($MILLION)
FIGURE 27.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE, 2019-2027 ($MILLION)
FIGURE 28.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE STRAIN/SPRAIN, 2019-2027 ($MILLION)
FIGURE 29.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS, 2019-2027 ($MILLION)
FIGURE 30.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS, 2019-2027 ($MILLION)
FIGURE 31.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN, 2019-2027 ($MILLION)
FIGURE 32.U.S. PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE PAIN, 2019-2027 ($MILLION)
FIGURE 33.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.BOEHRINGER INGELHEIM: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 38.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 39.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 41.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 42.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 43.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 44.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 45.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 46.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 47.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 49.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 50.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 51.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 52.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 53.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 54.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 55.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 56.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 57.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)

SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3249

This license allows only one user to access the PDF.
Electronic (PDF)

$3423

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$4774

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Electronic (Excel)

$2038

This license allows users/teams to use the numbers mentioned in the Excel sheet within an organisation
Add to Cart
Buy Now (10% Discount)
INQUIRE FOR DISCOUNT
HAVE A QUERY?
INQUIRE ABOUT REPORT EMAIL US
OUR CUSTOMER
Bioinformatics Barcelona
SIMILAR REPORTS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICIES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions